treating COVID-19, COPD and Asthma
Under Dr. Salerno's care 30 COPD, Asthma and COVID-19 patients varying in age from 12 to 86 years old were prescribed Inspiritol and reported substanative clinical improvements with no significant reported adverse events.
At the core of Inspiritol are compounds that serve to reestablish the anti-oxidant oxidant balance in the lungs while reducing or eliminating inflammation associated with most known pulmonary disease and infections.
Breaking the Long COVID and ME/CFS cycle of immune dysregulation with Inspiritol
Long-COVID and ME/CFS (Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome) result from aberrant responses to immunological triggers like an infection which results in a permanently dysregulated immune system as a result of over activation of certain T-Cells, their subsequent exhaustion and metabolic disruption .
Dr. Salerno Collaboration with Dr. Liisa Selin
Recently, Dr. Liisa Selin of UMass Chan Medical School, an Inspiritol collaborator, discovered similar immune responses in both Long-COVID and ME/CFS patients.
These include CD-8 T cell exhaustion, increased CD4+CD8+ T cells, type II interferon exhaustion and evidence of difficulty controlling persistent viral pathogens.
With the same biomarker analyses, they reported the treatment of Long-COVID and ME/CFS patients' using Inspiritol resulted in modulation of their immune system response towards a more normal profile in addition to sustained symptomatic relief.